Multiple Myeloma · Active Clinical Trials
As of 2026-10-21, the full China registry snapshot contains 64 active multiple myeloma interventional trials across 31 provincial-level regions and 316 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
Found 18 matching clinical trials
View Bispecific LandscapeA Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Formulation of TQB2934 for Injection in Participants with Malignant Plasma Cell Neoplasms
Locations & Centers
Zhongshan Hospital, Fudan University、The Second Affiliated Hospital of Soochow University、The First Affiliated Hospital of Xi'an Jiaotong University 等 14 家
Target / Modality
Bispecific antibody targeting BCMA×CD3
ELRANATAMAB Post-Trial Access: An Open-Label, Single-Arm Study for Multiple Myeloma Study Participants Continuing in Pfizer-Sponsored ELRANATAMAB Clinical Studies
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Peking University Third Hospital、Shandong Provincial Hospital 等 7 家
Target / Modality
bispecific antibody
An Open-Label, Two-Arm, Multicenter, Randomized, Phase III Study Evaluating the Efficacy and Safety of ELRANATAMAB (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Study Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible or Deferred Transplant
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital, Zhejiang University School of Medicine 等 17 家
Target / Modality
BCMA × CD3 bispecific antibody
A Multicenter, Open-label, Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of YKST02 in the Treatment of Relapsed/Refractory Multiple Myeloma
Locations & Centers
Beijing Chaoyang Hospital, Capital Medical University、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 13 家
Target / Modality
BCMA × CD3 bispecific antibody
A Phase III, Randomized Study Comparing Teclistamab in Combination With Subcutaneous (SC) Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With SC Daratumumab and Lenalidomide (Tal-DR) Versus SC Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Not Eligible or Not Planned for Autologous Stem Cell Transplantation as Initial Therapy
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital 等 32 家
Target / Modality
BCMA × CD3 bispecific antibody (MajestTEC-7 study)
A Randomized, Controlled, Multicenter, Open-Label Phase III Study Evaluating the Efficacy and Safety of QLS32015 for Injection Monotherapy Versus Investigator's Choice of Regimen in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、First Affiliated Hospital of Kunming Medical University 等 82 家
Target / Modality
GPRC5D/CD3 bispecific antibody
A Single-Arm, Open-Label, Multicenter Phase II Clinical Trial of GR1803 Injection for Efficacy, Safety, Pharmacokinetics, and Immunogenicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Target / Modality
BCMA × CD3 bispecific antibody
An Open-Label, Multicenter Phase I Clinical Study of SHR-9539 Injection Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Multiple Myeloma
Locations & Centers
West China Hospital of Sichuan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 28 家
Target / Modality
BCMA × CD3-targeting bispecific antibody
A Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University 等 23 家
Target / Modality
Trispecific antibody targeting GPRC5D, BCMA, and CD3
An Open-Label, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of F182112 in Combination with Different Dosing Regimens for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Bengbu Medical University、The First Affiliated Hospital of Chongqing Medical University 等 44 家
Target / Modality
Recombinant Humanized Anti-BCMA/CD3 Bispecific Antibody for Injection
A Phase I Clinical Study Evaluating the Tolerability and Pharmacokinetics of TQB2029 for Injection in Participants with Multiple Myeloma
Locations & Centers
West China Hospital, Sichuan University、Zhongshan Hospital, Fudan University、Jiangsu Province Hospital 等 12 家
Target / Modality
Bispecific antibody targeting GPRC5D×CD3
A Multicenter, Open-label Phase II Study Evaluating QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、Nanyang Central Hospital 等 50 家
Target / Modality
T-cell redirecting bispecific antibody
A Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
Peking University People's Hospital、The First Affiliated Hospital of Henan University of Science and Technology、Qingdao Municipal Hospital 等 21 家
Target / Modality
GPRC5D × CD3 bispecific antibody
A Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Locations & Centers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital 等 39 家
Target / Modality
Trispecific antibody targeting BCMA, CD3, and GPRC5D
A Phase Ib, Open-Label, Single-Arm, Multicenter Study Evaluating the Pharmacokinetics, Safety, and Efficacy of CEVOSTAMAB in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Nanchang University 等 4 家
Target / Modality
T-cell redirecting bispecific antibody
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Locations & Centers
The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center 等 19 家
Target / Modality
BCMA × CD3 bispecific T-cell engager (BiTE)
A Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University 等 11 家
Target / Modality
GPRC5D × CD3-targeting bispecific antibody
A Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
PKU Healthcare Luzhong Hospital
Target / Modality
Recombinant anti-BCMA and CD3 bispecific antibody injection